LICeNSE AND OPTION AGREEMENT BY AND BETWEENLicense and Option Agreement • November 9th, 2016 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This LICENSE AGREEMENT (this “Agreement”) is made and effective as of the Effective Date (as defined below) by and between TRACON Pharmaceuticals, Inc., a Delaware corporation (“TRACON”) and Janssen Pharmaceutica N.V. (“Janssen”). Each of TRACON and Janssen is sometimes referred to herein individually as a “Party” and collectively as the “Parties.” In the event a Party assigned the License and Option Agreement (as defined below) in its entirety prior to the Effective Date (as defined below) pursuant to Section 13.6 of the License and Option Agreement, or a lawful successor of a Party became bound by the License and Option Agreement prior to the Effective Date, the references to such Party in this Agreement shall be deemed to refer to such permitted assignee or lawful successor.
INVESTOR AGREEMENT By and Between JOHNSON & JOHNSON INNOVATION-JJDC, INC. AND TRACON PHARMACEUTICALS, INC. Dated as of September 27, 2016Investor Agreement • November 9th, 2016 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INVESTOR AGREEMENT (this “Agreement”) is made as of September 27, 2016, by and among Johnson & Johnson Innovation-JJDC, Inc., a New Jersey corporation (“Investor”), with its principal place of business at 410 George Street, New Brunswick, New Jersey 08901 and TRACON Pharmaceuticals, Inc., a Delaware corporation (the “Company”), with its principal place of business at 8910 University Center Lane, Suite 700, San Diego, California 92122.
STOCK PURCHASE AGREEMENT By and Between JOHNSON & JOHNSON INNOVATION-JJDC, INC. AND TRACON PHARMACEUTICALS, INC. Dated as of September 27, 2016Stock Purchase Agreement • November 9th, 2016 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of September 27, 2016, by and between Johnson & Johnson Innovation-JJDC, Inc. (the “Investor”), a New Jersey corporation with its principal place of business at 410 George Street, New Brunswick, New Jersey 08901, and TRACON Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, with its principal place of business at 8910 University Center Lane, Suite 700, San Diego, CA 92122.
